Literature DB >> 33597866

Saponins in Chinese Herbal Medicine Exerts Protection in Myocardial Ischemia-Reperfusion Injury: Possible Mechanism and Target Analysis.

Ruiying Wang1,2,3,4,5, Min Wang1,2,3,4,5, Jiahui Zhou1,2,3,4,5, Daoshun Wu1,2,3,4,5, Jingxue Ye1, Guibo Sun1,2,3,4,5, Xiaobo Sun1,2,3,4,5.   

Abstract

Myocardial ischemia is a high-risk disease among middle-aged and senior individuals. After thrombolytic therapy, heart tissue can potentially suffer further damage, which is called myocardial ischemia-reperfusion injury (MIRI). At present, the treatment methods and drugs for MIRI are scarce and cannot meet the current clinical needs. The mechanism of MIRI involves the interaction of multiple factors, and the current research hotspots mainly include oxidative stress, inflammation, calcium overload, energy metabolism disorders, pyroptosis, and ferroptosis. Traditional Chinese medicine (TCM) has multiple targets and few toxic side effects; clinical preparations containing Panax ginseng C. A. Mey., Panax notoginseng (Burk.) F. H. Chen, Aralia chinensis L., cardioprotection, and other Chinese herbal medicines have been used to treat patients with coronary heart disease, angina pectoris, and other cardiovascular diseases. Studies have shown that saponins are the main active substances in TCMs containing Panax ginseng C. A. Mey., Panax notoginseng (Burk.) F. H. Chen, Aralia chinensis L., and Radix astragali. In the present review, we sorted the saponin components with anti-MIRI effects and their regulatory mechanisms. Each saponin can play a cardioprotective role via multiple mechanisms, and the signaling pathways involved in different saponins are not the same. We found that more active saponins in Panax ginseng C. A. Mey. are mainly dammar-type structures and have a strong regulatory effect on energy metabolism. The highly active saponin components of Aralia chinensis L. are oleanolic acid structures, which have significant regulatory effects on calcium homeostasis. Therefore, saponins in Chinese herbal medicine provide a broad application prospect for the development of highly effective and low-toxicity anti-MIRI drugs.
Copyright © 2021 Wang, Wang, Zhou, Wu, Ye, Sun and Sun.

Entities:  

Keywords:  aralia saponins; ginsenosides; mechanism; myocardial ischemia-reperfusion injury; saponins; traditional Chinese medicine

Year:  2021        PMID: 33597866      PMCID: PMC7883640          DOI: 10.3389/fphar.2020.570867

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  5 in total

Review 1.  Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?

Authors:  Cong Chen; Lin-Tong Yu; Bai-Ru Cheng; Jiang-Lin Xu; Yun Cai; Jia-Lin Jin; Ru-Li Feng; Long Xie; Xin-Yan Qu; Dong Li; Jing Liu; Yan Li; Xiao-Yun Cui; Jin-Jin Lu; Kun Zhou; Qian Lin; Jie Wan
Journal:  Front Cardiovasc Med       Date:  2022-02-17

Review 2.  Molecular-Signaling Pathways of Ginsenosides Rb in Myocardial Ischemia-Reperfusion Injury: A Mini Review.

Authors:  Fitri Fareez Ramli; Adli Ali; Nurul 'Izzah Ibrahim
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

3.  Mechanism of Action of Flavonoids of Oxytropis falcata on the Alleviation of Myocardial Ischemia-Reperfusion Injury.

Authors:  Yang Guo; Ben-Yin Zhang; Yan-Feng Peng; Leng Chee Chang; Zhan-Qiang Li; Xin-Xin Zhang; De-Jun Zhang
Journal:  Molecules       Date:  2022-03-05       Impact factor: 4.411

4.  HSP70 protects H9C2 cells from hypoxia and reoxygenation injury through STIM1/IP3R.

Authors:  TianYu Liu; Zhaodong Juan; Bin Xia; GuanHua Ren; Zhen Xi; JunWen Hao; ZhongDong Sun
Journal:  Cell Stress Chaperones       Date:  2022-07-16       Impact factor: 3.827

Review 5.  Therapeutic targets by traditional Chinese medicine for ischemia-reperfusion injury induced apoptosis on cardiovascular and cerebrovascular diseases.

Authors:  Xiuli Cheng; Jin Hu; Xiaofeng Liu; Jonnea Japhet Tibenda; Xiaobo Wang; Qipeng Zhao
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.